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Aims Proteins with a PDZ (for PSD-95, DLG, ZO-1) and one to three LIM (for Lin11, Isl-1, Mec-3) domains are scaffolding
sarcomeric and cytoskeletal elements that form structured muscle fibres and provide for the link to intracellular sig-
nalling by selectively associating protein kinases, ion channels, and transcription factors with the mechanical stress–
strain sensors. Enigma homolog (ENH) is a PDZ–LIM protein with four splice variants: ENH1 with an N-terminal
PDZ domain and three C-terminal LIM domains and ENH2, ENH3, and ENH4 without LIM domains. We addressed
the functional role of ENH alternative splicing.
Methods
and results
We studied the expression of the four ENH isoforms in the heart during development and in a mouse model of heart
hypertrophy. All four isoforms are expressed in the heart but the pattern of expression is clearly different between
embryonic, neonatal, and adult stages. ENH1 appears as the embryonic isoform, whereas ENH2, ENH3, and ENH4
are predominant in adult heart. Moreover, alternative splicing of ENH was changed following induction of heart
hypertrophy, producing an ENH isoform pattern similar to that of neonatal heart. Next, we tested a possible
causal role of ENH1 and ENH4 in the development of cardiac hypertrophy. When overexpressed in rat neonatal
cardiomyocytes, ENH1 promoted the expression of hypertrophy markers and increased cell volume, whereas, on
the contrary, ENH4 overexpression prevented these changes.
Conclusion Antagonistic splice variants of ENH may play a central role in the adaptive changes of the link between mechanical
stress-sensing and signalling occurring during embryonic development and/or heart hypertrophy.
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1. Introduction
PDZ–LIM proteins play important roles in muscle and heart develop-
ment.1 These proteins combine two interaction modules, a PDZ
domain (named for the proteins PSD-95, DLG, ZO-1)2 and one to
three LIM domains (named for the proteins LIN-11, Isl-1, MEC-3).3
The PDZ–LIM protein family counts at least 10 members classified
in three subfamilies.4 The first subfamily has five members: ALP
(actinin-associated LIM proteins), Elfin, Mystique, LMO7, and RIL
(reversion-induced LIM protein).5 Proteins in this subfamily carry a
single PDZ domain and a single LIM domain. Two protein kinases
form the second subfamily: LIM kinase 1 (LMK1) and LIM kinase 2
(LIMK2), characterized by a PDZ domain, two LIM domains and a
tyrosine kinase domain.6 The members of the third subfamily are
characterized by one N-terminal PDZ domain and three tandem C-
terminal LIM domains. This family counts at least four members:
Enigma (LMP-1), Enigma homolog (ENH), Cypher (ZASP, Oracle),
and LMP-4 (LMP-2).7– 9
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In heart and skeletal muscle, PDZ and LIM domains are important
elements of adaptors, which connect mechanical sensors, embedded
in specialized cytoskeletal structures (e.g. Z-disc) to signalling pro-
teins. In the heart, proteins with PDZ and LIM domains are necessary
to allow embryonic development and adaptive remodelling in
response to stress and strain.1 Indeed, Cypher and ALP have been
shown to play two different but essential roles. ALP is essential in
the embryonic development of the sarcomeric and cytoskeleton
architecture in the right ventricular chamber.10 Cypher is not directly
involved in heart development, but it is essential to maintain the Z-line
structure of the sarcomere during muscle contraction.11
ENH is a PDZ–LIM protein expressed in the heart and other
tissues. The PDZ domain of ENH1 interacts with a-actinin and loca-
lizes ENH at the Z-disc in neonatal rat cardiomyocytes.12 First discov-
ered as a PKCb interacting partner,8 its biological function was so far
poorly understood. Recently, we identified two new binding partners
for ENH1 in cardiomyocytes, namely protein kinase D1, which plays a
critical role in the cardiovascular system13 and a1C, the pore subunit
of the L-type voltage-gated calcium channel.14 Thus ENH1 connects a
major signalling pathway with calcium entry required to sustain con-
tractile activity. Although the precise functional importance of these
interactions has yet to be demonstrated, these observations point
towards a key role for ENH in heart muscle.
By alternative splicing, ENH is diversified into at least four isoforms:
ENH18, ENH2, ENH3,12 and ENH415. ENH1 is the only isoform that
contains the three LIM motifs at the C-terminal domain. ENH2,
ENH3, and ENH4 only retain the N-terminal PDZ domain. The
four ENH isoforms are expressed in heart and skeletal muscle and
are conserved across rat, mouse, and human species, suggesting
their physiological importance.8,12,15,16
What could be the functional relevance of the splice variants? To
address this question, we have assessed quantitatively the expression
of the ENH splice isoforms in heart at different developmental stages
and in a mouse model for cardiac hypertrophy. We found that the
four splice variants are differentially expressed in embryo, neonatal,
and adult heart. ENH1 is predominant in embryonic heart, whereas
the adult heart expressed mainly the truncated isoforms ENH2,
ENH3, and ENH4. In heart, hypertrophy induced by transaortic con-
striction (TAC) in mice ENH isoform expression reverted to a pattern
similar to neonatal/embryonic hearts. Furthermore, ENH1 overex-
pressed in neonatal cardiomyocytes was found to promote the devel-
opment of hypertrophy, whereas silencing of ENH1 prevented
hypertrophy. Surprisingly, overexpression of ENH4 also blocked the
development of hypertrophy. Taken together, the data reported
here show that alternative splicing of ENH transcripts produces antag-
onistic ENH isoforms during heart development: embryonic isoform
ENH1 may cause, whereas the adult isoform ENH4 may prevent
cardiac hypertrophy.
2. Methods
2.1 TAC surgery
Animals used in the present study were treated in conformity with the
Guide for the Care and Use of Laboratory Animals published by the
NIH (Publication No. 85-23, 1996). Protocols and use of animals were
approved by Committee for Animal Experiments of both Nagaoka Uni-
versity of Technology and Tokyo Institute of Technology. Transverse
thoracic aortic constriction was performed as described17 on
8-week-old adult mice (C57BL/6, the Jackson Laboratory, Bar Harbor,
ME, USA). At hypertrophic phase (8 days after banding) after surgery,
animals from the experimental and sham-operated groups were sacrificed
and the hearts were removed. Left ventricles were weighed and quickly
frozen in liquid nitrogen for total RNA extraction.
2.2 Cell culture
Neonatal rat ventricular myocytes were prepared as described.14 The car-
diomyocytes were transferred to culture plates, and fibroblasts were
removed by adhesion onto the plates for 1 h. The cardiomyocytes were
then plated overnight and maintained in DMEM, containing 10% foetal
bovine serum, 2 mM L-glutamine, 100 U/mL penicillin, and 100 mg/mL
streptomycin.
2.3 Real-time PCR
Total RNA (1 mg) was used for RT–PCR with the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems) according to the manufac-
turer’s instructions. The synthesized cDNA (50 ng of RNA content),
250 nM primers pairs, 250 nM probes, and Absolute QPCR ROX Mix
(AB gene) were mixed in a final volume of 25 mL and used for quantitative
real-time PCR. The PCR reaction was carried out in triplicates in 96-well
plates with ABIPrism 7000 Sequence Detection System (Applied Biosys-
tems). The primers and TaqMan probes used in the experiments are
shown in Table 1. As for standard curves, we amplified each ENH frag-
ment with the primer pairs and inserted into pGEM T-easy (Promega).
After confirmation of the sequence, the plasmids were used for standard
curves.
2.4 RNA interference
The ‘hairpin strategy’ was used to design short-interfering RNA.18 The
specific hairpin sequence of ENH1 corresponding to positions 1698–
1718 (RNAi1) or 1452–1472 (RNAi2) of coding sequence were used
to amplify the vector carrying the U6 promoter as described.14 We
selected sequences unique for rat ENH1 in the NCBI cDNA database.
2.5 Adenovirus vector constructs
Recombinant human adenoviruses-5 encoding ENH1-FL, ENH4-FL, ENH1
RNAi, and control RNAi were constructed, amplified, and purified as
described.14
2.6 RNase protection assay
RNase protection assay (RPA) was performed as described.14 Total RNA
was extracted from neonatal rat cardiomyocytes with an acid phenol–
guanidinium reagent (TRI-Reagent, Molecular Research Center, Inc.)
according to the manufacturer’s instructions. The riboprobe was prepared
from the rat ENH cDNA and subcloned in pGEM-T-easy (Promega).
Transcription with T7 RNA polymerase of the BamHI-linearized plasmid
yielded a riboprobe of 366 nucleotides, and protected fragments of
207 nt for ENH1, 225 nt for ENH2, 258 nt for ENH3, and 276 nt for
ENH4. A rat GAPDH probe was used as a loading control. The
GAPDH plasmid digested with HinfI produced a riboprobe of 185 nt
and a 154 nt protected band after RNase digestion. Autoradiographic
signals were detected with a PhosphoImager (Molecular Dynamics, Inc.).
2.7 Patch-clamp
The capacitance of single neonatal rat cardiomyocyte was recorded by
patch-clamp in the whole-cell configuration and voltage-clamp mode.14
The bath solution contained 125 mM N-methyl-glucamine, 5 mM 4-
aminopyridine, 20 mM tetraethylammonium chloride, 2 mM CaCl2,
2 mM MgCl2, 10 mM D-glucose, and 10 mM HEPES, pH 7.4. The patch pip-
ettes solution contained 130 mM CsCl, 10 mM EGTA, 3 mM MgATP,
0.4 mM LiGTP, and 25 mM HEPES, pH 7.2. The reference electrode
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was placed in a KCl solution linked to the bath with an agar bridge, redu-
cing the liquid junction potential to negligible values. The cell was voltage-
clamped using an Axopatch 200B amplifier (Axon CNS, Molecular
Devices) at a holding potential of 290 mV. The currents were filtered
at 1–2 kHz and sampled at 5 kHz using a Digidata 1322A (Axon CNS).
3. Results
3.1 Rat enh gene structure and splice
variants expressed in the heart
The enigma homolog (enh) gene is located on chromosome 2 (locus
2q44) of rat genome and the chromosome 3 (locus 3H3) of the
mouse genome. The rat enh gene spans 11.96 kb and consists of 18
exons. Figure 1A shows a schematic representation of the genomic
organization of the rat enh gene. The first two exons encode a
50-untranslated region; the coding region extends from exon 3 to
exon 18. Four splice variants encoded by the enh gene have been
described.8,12,15,16 Figure 1B shows the schematic exonic composition
of the four ENH splice variants. ENH1 is the only isofom containing
the three LIM motifs in its C-terminal end. ENH2, ENH3, and
ENH4 are truncated isoforms that only retain the N-terminal PDZ
domain. Exon 12 contains a stop codon; hence skipping of exon 12
leads to the expression of the long isoform ENH1, whereas inclusion
of exon 12 produces the three isoforms ENH2, ENH3, and ENH4
with truncated C-terminal. Differential expression between the trun-
cated isoforms ENH2, ENH3, and ENH4 is the result of alternative
skipping or rearrangement of exons 6–9.
To detect which splice variants of ENH are expressed in heart, we
designed a single anti-sense RNA probe spanning exons 6–12
(Figure 1A, red line). The probe and the protected RNA fragments
after RNase digestion are indicated as a red line on each ENH
splice variant in Figure 1A and B. Analysing total RNA extracted
from isolated ventricular neonatal rat cardiomyocytes, this probe
allowed us simultaneous detection of the four ENH splice variants
by RPA (Figure 2A). ENH1 and ENH2 are strongly expressed,
whereas the expression of ENH3 and ENH4 is much lower.
Using the same RPA probe, splicing of the ENH transcript was ana-
lysed in rat hearts at different developmental stages: embryonic, neo-
natal, and adult (Figure 2B). Striking changes in the expression pattern
of ENH isoforms were observed between embryonic, neonatal, and
adult heart. In the adult heart, expression of ENH3 and ENH4 was
markedly increased compared with neonatal heart, whereas the
expression of ENH1 and ENH2 was reduced. In contrast, in embryo-
nic heart, ENH1 was the most abundant splice variant, different from
the neonatal pattern in which the RPA signals from ENH1 and ENH2
are equivalent, and ENH3 is also strongly expressed. The comparison
of the RPA signals suggests that during heart development splicing of
ENH shifts from the embryonic isoform ENH1 towards the adult iso-
forms ENH2, ENH3, and ENH4.
For an alternative quantitative assessment of ENH splice variants by
real-time PCR, we designed primers and probes to measure the
expression of ENH1 and ENH3 variants. The results of real-time
PCR (Figure 2C and D) corroborate the RPA data (Figure 2B). Relative
to total RNA, the expression of ENH1 is the highest in neonatal heart,
and similar in embryonic and adult heart. On the other hand, ENH3 is
hardly detectable in embryonic heart tissue and low in neonatal heart,
but highly expressed in adult heart tissue. This shift in the levels of
ENH1 isoforms is best explained by a change of the alternative spli-
cing of ENH in intron 11. In adult heart, exon 12 is included leading
to the short isoforms, whereas in embryonic and neonatal heart,
exon 12 with its stop codon is spliced out, leading to the expression
of ENH1. Note that this latter type of splicing is maintained in adult
heart tissue, possibly in immature cardiomyocytes.
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Table 1 Primers and probes sequences used for real-time PCR
Forward 50 –30 Reverse 50 –30 Probe 50 –30
Rat ENH1 GGC TCC ACC TGG CAT GAC AAA ATG TCT GCC CTT CCA AAC
TT
FAM-TTG CTT TGT GTG CTC CGT GTG TTG
TG-BHQ1/TAMRA
Rat ENH3 ACC AGC GTG TGT TCC GAG T CGT TTG GGT GGA ATT TTC ACA FAM-CAG CAA AAT GGT AAC CCT GGC A-BHQ1/
TAMRA
Rat ENH4 GCT GTC CAG AAG AAA GCA
CA
TGT GAT AAA ACT CCG TGT TGC FAM-ACC CAA ACG CCC ACC AAG AA-BHQ1/
TAMRA
Rat cyclophilin A TCT GGG ATA CAC TTG GCA
TGA T
TCA AAT TTC TCT CCG TAG ATG
GAC TT
FAM-ACA CGC CAT AAT GGC ACT GGT GG-BHQ1/
TAMRA
Mouse ENH1 TCT GGG ATA CAC TTG GCA
TGA T
GCC CTT CCA AAC TTT CAC AAC A FAM-CTT GCT TTG TGT GCT CTG-BHQ1/TAMRA
Mouse ENH3 AGA GGA TCC CAG GGT GAC
ATT A
CGT TTA GGT GGA ATT TTC ACA FAM-CAG CAA AAT GGT AAC CCT GGC A-BHQ1/
TAMRA
Mouse ENH4 CCG TCC AGA AGA AAA CAC
AC
TGT GAT AAA ACT CCG TGT TGC FAM-CCA CCT AAA CGC CCA CCA AGA-BHQ1/
TAMRA
Mouse cyclophilin A TGT GCC AGG GTG GTG ACT T TCA AAT TTC TCT CCG TAG ATG
GAC CT
FAM-ACA CGC CAT AAT GGC ACT GGC GG-BHQ1/
TAMRA
Rat ANP ATG GGC TCC TTC TCC ATC
AC
CAT CTT CTC CTC CAG GTG GTC
Rat BNP GGG CTG TGA CGG GCT GAG
GTT
AGT TTG TGC TGG AAG ATA AGA
Rat betaMHC GCA GCT TAT CAG GAA GGA
ATA C
CTT GCG TAC TCT GTC ACT C
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3.2 Expression of ENH isoforms in diseased
mouse heart
The expression of the embryonic isoform ENH1 in adult heart could
be an indicator of heart de-differentiation linked to hypertrophic
growth. To test this, we used hearts from mice operated by TAC
leading to heart hypertrophy and heart failure. ENH1 expression
was measured by real-time PCR in mice hearts following TAC or
sham operation (Figure 3). In the hypertrophic phase (1 week after
TAC, Figure 3A), the amount of ENH1 was significantly higher than
in TAC-operated hearts compared with sham-operated hearts. On
the contrary, the cardiac expression of ENH4 was significantly
lower in the TAC-operated than in sham-operated animals. The
cardiac expression of ENH3 was also lower in the TAC-operated
than in sham-operated animals but not significantly (see Supplemen-
tary material online, Figure S1). Eight weeks after TAC when the
mice have become prone to heart failure, ENH1 was no longer signifi-
cantly elevated over sham-operated hearts (Figure 3B). However,
expression of ENH3 (see Supplementary material online, Figure S1)
and ENH4 were significantly lower in TAC vs. sham mice. These
results suggest that in cardiac hypertrophy, the expression of ENH1
is favoured, whereas ENH4 is reduced. Hence, with regard to ENH
isoform expression, hypertrophic resembles neonatal heart.
3.3 Role of ENH1 in a neonatal rat
cardiomyocyte model of hypertrophy
Adaptor PDZ–LIM proteins such as ENH are capable to translate
mechanical stress signals sensed in the Z-disc to intracellular signalling
cascades and gene expression.1 Indeed, in cardiomyocytes, ENH1
interacts with structural and signalling proteins, i.e. several isoforms
of protein kinase C,8 protein kinase D1,14 and a-actinin.12 In the
mouse disease model above, arterial constriction leading to mechan-
ical stress caused heart hypertrophy. The associated changes in ENH
splicing strongly suggested its implication.
To test a possible causal role of ENH1 in the development of heart
hypertrophy, we overexpressed a flag-tagged ENH1 in rat neonatal
ventricular cardiomyocytes. Rat ENH1 cDNA was transferred using
an adenoviral vector.14 To monitor quantitatively changes in cell
volume, electrical capacitance of the whole-cell membrane was
measured by the patch-clamp technique. As is shown in Figure 4A,
overexpression of ENH1 significantly increased membrane capaci-
tance and hence cell volume of neonatal rat cardiomyocytes in com-
parison to control cells.
Furthermore, the mRNA levels of three markers of cardiac hyper-
trophy, namely ANP, BNP, and bMHC, were also significantly
increased upon ENH1 overexpression (Figure 4B). Taken together,
these results suggest that ENH1 promotes the development of cardi-
omyocyte hypertrophy.
To verify that ENH1 indeed participates in the development of car-
diomyocyte hypertrophy, we silenced the expression of ENH1 using
small hairpin RNA (shRNA) targeting ENH1 and delivered by adeno-
viral vectors.14 We first validated the efficiency of this shRNA to
knockdown the endogenous ENH1 expression as well as the stimu-
lated increased expression of ENH1 in ventricular neonatal rat cardi-
omyocytes (Figure 5). Forty-eight hours after adenovirus treatment,
the cardiomyocytes were exposed for 30 h to phenylephrine
(20 mM), aldosterone (1 mM), or endothelin I (10 nM) used as hyper-
trophic stimuli. The expression of ENH1 was then measured by
Figure 1 Scheme of the rodent ENH gene and the splice variants of its transcript. (A) Schematic representation of the genomic organization of the
rat ENH gene with 18 exons. Translation start codon (Met) is located on the third exon. There are two stop codons (Ter): the first located in the 12th
exon, the second in the 18th exon. The PDZ domain is encoded by the third and fourth exons; the three LIM domains are encoded by the 13th to
18th exons. The red line indicates the probe used RPA spanning coding sequences from exon 7 to 12. (B) Schematic representation of the exonic
organization of the four known enh splice variants. The red lines indicate the length of the RPA probe protected from RNase digestion by hybridization
to the various ENH isoforms.
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real-time PCR. All three stimuli induced a significant increase in the
expression of ENH1 similar to the observation in TAC-operated
mice (Figure 3). This effect was efficiently prevented by ENH1 shRNA.
With this effective knockdown of ENH1, we investigated the role of
ENH1 in the development of heart hypertrophy. As is shown in
Figure 6A, cardiomyocyte cell size measured as whole-cell membrane
capacitance was significantly increased by three hypertrophic stimuli:
phenylephrine, aldosterone, or endothelin 1. These effects were not
seen after ENH1 silencing. Without any treatment, ENH1 silencing
did not result in any significant change in membrane capacitance
(Figure 6A). These data support a central role of ENH1 in the increase
of volume of cardiomyocytes upon stimulation with hypertrophic
stimuli acting via various intracellular signalling pathways.
As shown in Figure 6B, ENH1 silencing also affected the expression
of three marker genes for cardiac hypertrophy: ANP, BNP, and
bMHC. The mRNA levels of these genes are increased upon aldoster-
one, phenylephrine, and ET1 stimulation (Figure 6B, upper panels).
ENH1-RNAi blocked completely the induction of the cardiac hyper-
trophic marker genes (Figure 6B, middle panels). These results conso-
lidate the role of ENH1 in the regulation of ventricular cardiomyocyte
expansion stimulated by hormones which signal vascular stress and
hypertension. Interestingly, the silencing of ENH1 changed gene
expression and expansion only of cardiomyocytes which were stimu-
lated, whereas steady-state functions of non-stimulated cells appeared
unaffected.
3.4 The alternatively spliced isoform ENH4
is an antagonist of ENH1
ENH expression in ventricular cardiomyocytes in vivo varies with
development and vascular stress not only by changes in transcription
but also by changes in alternative splicing. Vascular stress favours
the ‘embryonic’ ENH1 isoform, which plays a causal role for the
development of cardiac hypertrophy, whereas in normal adult heart,
the short isoforms ENH2, ENH3, and ENH4, which are lacking the
C-terminal LIM domains, are predominant. Furthermore, it has been
suggested that the LIM domain-deficient ENH isoforms might act as
antagonist of ENH1.12 To test this hypothesis, a FLAG-tagged
ENH4 (ENH4-FL) was ectopically expressed in ventricular neonatal
rat cardiomyocytes using adenoviral vector. Cardiomyocytes were
then stimulated for 30 h with aldosterone (1 mM), phenylephrine
(20 mM), or endothelin-1 (10 nM). All three stimuli increased cell
size measured as whole-cell membrane capacitance. Stimulated cardi-
omyocyte hypertrophy was totally suppressed in ENH4-FL expressing
cardiomyocytes after stimulation (Figure 6A). Importantly, in a non-
stimulated state, no change in whole-cell membrane capacitance
was observed upon ENH4-FL overexpression (Figure 6A, third
column).
The stimulated increase in the expression of the hypertrophy
marker genes ANP, BNP, and bMHC was also efficiently prevented
by the overexpression of ENH4-FL in neonatal rat cardiomyocytes
Figure 2 Expression of the four ENH splice variants in heart at various stages of development. (A) Autoradiography of an RPA experiment using
probes for ENH and for the housekeeping gene GAPDH as control. Twenty microgram of total RNA extracted from ventricular neonatal rat car-
diomyocytes were hybridized with both the ENH and the GAPDH probes before RNase digestion. The autoradiography shown is representative
of four independent experiments. (B) Autoradiography of an RPA experiment with 20 mg of total RNA extracted from adult, embryo or neonatal
rat hearts hybridized to ENH and GAPDH probes. This particular autoradiography is representative of three independent experiments. (C and D)
ENH1 (C) and ENH3 (D) mRNA measured by real-time PCR in 50 ng of total RNA extracted from embryonic, neonatal, and adult rat hearts.
Shown are the means and SD of three independent experiments (*P, 0.002).
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Figure 3 Expression of the splice variants ENH1 and ENH4 in diseased heart of mice. ENH splice-variant expression was examined in mouse heart
after transaortic constriction (TAC) leading to cardiac hypertrophy and heart failure. (A) ENH1 (upper) and ENH4 (lower) during the development of
cardiac hypertrophy 1 week after TAC or sham operation. ENH splice variants were quantified by real-time PCR using 50 ng of total RNA. (B) ENH1
(upper) and ENH4 (lower) in mice prone to heart failure 8 weeks after TAC or sham operation. ENH splice variants were quantified by real-time PCR
using 50 ng of total RNA. Shown are means and SD of three independent experiments from three mouse hearts for each experimental conditions;
*significantly different from sham-operated control (P, 0.02).
Figure 4 ENH1 overexpression induced hypertrophy of ventricular neonatal cardiomyocytes. (A) The volume of cardiomyocytes was determined
by measuring the electrical capacitance of the plasma membrane using the whole-cell configuration of the patch-clamp technique. Cells were plated on
glass coverslips and infected with ENH1-FL adenovirus. The capacitance was measured 48 h after infection. Shown are means and SD of four inde-
pendent cell preparations (n ¼ 25 cells per condition). *P, 0.01. (B) Hypertrophic marker gene expression. Cardiomyocytes were infected with
ENH1-FL adenovirus for 48 h. The relative mRNA expression of three marker genes of cardiac hypertrophy, ANP (left), BNP (middle), and
bMHC (right) were measured by real-time PCR using 100 ng of total RNA. Shown are the means and SD of three independent cell preparations.
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(Figure 6B, lower panels). Taken together, the results presented in
Figure 6 strongly suggest that ENH4 can efficiently prevent cardiomyo-
cyte hypertrophy most likely by acting as an antagonist of ENH1. This
confirms the central role of ENH isoforms in the development of
heart hypertrophy.
4. Discussion
We report here the changes in the expression of the ENH splice var-
iants at three development stages of the heart (embryonic, neonatal,
and adult) and in vascular stress-induced cardiac disease. We present
evidence that the (embryonic) ENH1 isoform is not only up-regulated
during cardiac hypertrophy, but plays a central role promoting the
expression of marker genes and an increase in cardiomyocyte cell
volume. Strikingly, overexpression of ENH4, a splice variant lacking
the three LIM motifs, prevented ventricular cardiomyocyte hypertro-
phy induced by vascular stress hormones, suggesting that ENH4 acts
as a natural antagonist for ENH1.
Recent genome-wide studies have shown that 70–80% of the
human genes are alternatively spliced and that a substantial part of
the alternative splicing events are conserved in evolution (10–20%
between mouse and man).19 It is thus quite evident that the functions
of many gene products can only be appreciated by considering the
interplay between their various alternatively spliced isoforms. This is
well illustrated here: the different isoforms of the PDZ–LIM domain
scaffolding protein ENH have strikingly distinct adaptor functions:
ENH2, ENH3, and ENH4 which lack the LIM domains will no
longer associate with signalling proteins and transcription factors
but will maintain the selective association with cytoskeletal elements
such as actin and a-actinin.12–15,20 Given that we show here by gene
silencing a causal relationship between ENH1 expression and ventri-
cular cardiomyocyte hypertrophy (Figures 5 and 6), we could have
anticipated that overexpression of a LIM-less ENH isoform such as
ENH4 could prevent hypertrophy (Figure 6). Indeed, ENH4 most
likely acts as a dominant-negative inhibitor of ENH1 by competing
with its PDZ domain for the association with the cytoskeletal proteins
such as actin and a-actinin. ENH4 may thus replace ENH1 in the
Z-disc complex changing potentially composition, architecture and
functioning of this important regulatory multi-protein assembly.1
Stimuli leading to cardiac hypertrophy favour the (embryonic)
ENH1 isoform and repress ENH4. This suggests that hormones
which signal vascular stress change the alternative splicing mechanism
predominant in mature adult heart back to those which prevail in
embryonic or neonatal heart. This is consistent with the
Figure 5 ENH1 silencing in neonatal rat cardiomyocytes. To
silence the expression of ENH1, specific shRNA were delivered
into ventricular neonatal rat cardiomyocytes by adenoviruses. Cardi-
omyocytes were first treated with ENH1-RNAi for 48 h and then
stimulated with phenylephrine (20 mM), aldosterone (1 mM), or
endothelin I (10 nM) for 30 h. The quantitative amount of ENH1
mRNA was determined by real-time PCR using 50 ng of total
RNA. Data shown are means and SD of three independent measure-
ments from three independent cell preparations (*P, 0.0002 and
**P, 0.0001).
Figure 6 ENH1 silencing or ENH4 overexpression prevent cardi-
omyocyte hypertrophy. (A) The volume of cardiomyocytes was
determined by measuring the electrical capacitance of the plasma
membrane using the whole-cell configuration of the patch-clamp
technique. Cells were plated on glass coverslips then either
exposed to adenovirus delivering either ENH1-specific shRNA for
48 h or adenovirus delivering cDNA coding for FLAG-tagged
ENH4 (ENH4-FL) for 24 h. Cells were then stimulated with phenyl-
ephrine (20 mM), aldosterone (1 mM), or endothelin I (10 nM) for
30 h before proceeding to the whole-cell membrane capacitance
measurements. Shown are means and SEM of four independent
cell preparations (n ¼ 20 to 30 cells per condition); *P, 0.02.
(B) Hypertrophic marker gene expression was measured by
real-time PCR. Cells were treated with phenylephrine (PE; 20 mM),
aldosterone (Aldo; 1 mM), or endothelin I (ET1; 10 nM) for 30 h.
The relative mRNA expression (RA) of cardiac genes was measured
by real-time PCR using 100 ng of total RNA. Upper lane shows the
expression of ANF (left), BNP (middle), and bMHC (right) in control
conditions. Middle lane shows the expression of ANF (left), BNP
(middle), and bMHC (right) in cells treated with ENH1 shRNA
48 h prior to stimulation. Lower lane shows the expression of
ANF (left), BNP (middle), and bMHC (right) in cells overexpressing
ENH4-FL for 24 h prior to stimulation. Shown are means and SD of
three independent cell preparations; *P, 0.002.
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transcriptional re-activation of several foetal genes during cardiac
hypertrophy.21 A similar change in alternative splicing has been
reported for the large embryonic isoform N2BA of the giant
protein Titin whose expression is up-regulated in patients with
dilated cardiomyopathy.22 Thus, ENH is a new example of genes
whose expression during cardiac hypertrophy returns to foetal
pattern.
PDZ–LIM protein family members other than ENH also generate
various alternatively spliced isoforms.6,23 Alternative splicing allows
a tissue specific expression of the different PDZ–LIM protein iso-
forms, e.g. the cardiac or skeletal muscle specific isoforms of
Cypher gene products.23 Changes in the expression of the different
splice variant isoforms during development occur not only for ENH
(this study) but also for LIMK1 and LIMK2.6 Scaffolding by PDZ–
LIM proteins is extremely versatile. Not only are there at least 10
genes which encode for PDZ–LIM proteins, but alternative splicing
provides a large repertory of different isoforms. This makes it possible
that PDZ–LIM proteins can selectively adapt elements of the cytoske-
leton with mechanical stress sensors and signalling molecules relating
vascular stress.1 Furthermore, the same family can also structure the
specific and highly localized interaction between signalling protein
kinases and ion channels.14 To characterize the precise function of
each of these multiple PDZ–LIM protein isoforms in specific tissue
and sub-cellular localization and to understand the functional impor-
tance of changes in splicing occurring during development and disease
present an impressive challenge to future research.
ENH1 silencing prevented the stimulated hypertrophy of ventricu-
lar neonatal cardiomyocytes, whereas its overexpression promoted
hypertrophy (Figures 5 and 6). ENH1 interacts with PKD114 a
serine/threonine kinase required for pathological cardiac remodel-
ling.24 In the heart, PKD1 phosphorylates transcription factors,25
histone deacetylase,26 sarcomere proteins,27 and a cardiac calcium
channel.14 ENH1 might play a role in the scaffolding PKD1 at different
cellular localization to reach its various targets. Moreover in the brain,
ENH1 has been shown to interact with Id2,20 a transcriptional repres-
sor, which also plays an essential role in cardiac differentiation.28 We
are now investigating the precise role of these complex ENH1 func-
tions in pathological cardiac remodelling. ENH illustrates well the
challenge to describe in a comprehensive manner the molecular path-
ology of heart diseases which may involve a multitude of PDZ–LIM
protein isoforms.
The mechanisms regulating the splicing of ENH are currently being
investigated. Indeed, little is known about the splicing factors and
mechanisms which control PDZ–LIM protein gene products. The
splice factor ASF/SF2 has been shown to be required for the specific
expression of the cardiac isoform of cypher.29 Given the decisive role
for cardiomyocyte development and disease of the different ENH iso-
forms shown here, it would be of interest to identify the splicing
factors and mechanism regulating the expression of the various
ENH isoforms. Furthermore, it will be important to determine
common elements which may govern splicing in the family of PDZ–
LIM protein genes in various cells and tissues.
In summary, we have shown that the ENH splice variants are
expressed differentially during the development of the heart and
that in cardiac hypertrophy the pattern of expression is similar to
that observed in embryonic or neonatal heart. ENH1 re-expressed
during cardiac hypertrophy plays an active role in the remodelling
of cardiomyocytes. Finally, we also show that ENH4, a short splice
variant lacking the three LIM domains, acts as an antagonist of
ENH1. This latter finding might provide a clue of how to target
ENH1 for the prevention of cardiac hypertrophy.
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